#Knoxville #AMR Clinical #Kari Delahunty #Dr. William Smith

AMR Clinical Announces Leadership Transition

AMR Clinical, a prominent integrated research site organization, has declared a significant shift in leadership. Effective December 1, 2025, Dr. William B. Smith, the founding CEO since the company’s consolidation in 2017, will transition to the role of Vice Chairman of the Board of Directors. This strategic move aims to pave the way for Kari L. Delahunty, currently the Chief Operating Officer, who will assume the position of Chief Executive Officer and join the Board at the same time.

For over 30 years, Dr. Smith has played a pivotal role in steering AMR Clinical and its previous iterations through extensive growth and diversification in therapeutic areas. His leadership has been critical, particularly during the company's recapitalization by Curewell Capital.

David P. King, Chairman of the Board of Directors, lauded Dr. Smith’s profound impact, stating, "On behalf of the Board of Directors, I would like to express our appreciation to Dr. Smith for his long-standing leadership and vision, which have been instrumental to AMR's success. He is an innovator and thought leader in clinical research, and we are pleased that he will remain involved with AMR Clinical as Vice Chairman of the Board."

Kari Delahunty has established her reputation in the clinical research sector thanks to her strategic insight and operational prowess. Her background includes significant global positions in clinical development, strategy, and innovation. Before her tenure at AMR Clinical as COO, she served as President of Life Sciences at Shearwater Health, where she spearheaded growth and development. Her career milestones also encompass an array of increasing responsibilities at Syneos Health, culminating as Senior Vice President of Corporate Strategy.

“I’m honored to take the helm at AMR Clinical at such a pivotal point in its journey,” stated Delahunty. “The company is dedicated to delivering high-quality clinical research, and I look forward to guiding our talented team to enhance patient experiences, deepen partnerships, and drive shareholder value. Building upon our legacy is a challenge I fully embrace.”

Dr. Smith expressed his confidence in Ms. Delahunty, saying, "It has been a privilege to lead AMR Clinical, and I trust that Kari is the ideal person to move the company forward. She will emphasize AMR Clinical's expansive therapeutic range in clinical research, leveraging her skills in operational scalability and data-driven approaches, which align perfectly with our vision for ongoing growth.”

Michael Dal Bello, Partner at Curewell Capital and Board Member at AMR Clinical, acknowledged Dr. Smith’s contributions over the years. *